.After a few years in biotech, Mike Quigley, Ph.D., is actually coming back to the pharma crease, occupying the top scientific research spot at Sanofi.Quigley is going to start Sept. 30 as the French Big Pharma’s chief scientific police officer and also international director of research, Sanofi informed Tough Biotech in an emailed declaration.Quigley is switching out Frank Nestle, M.D., who left Sanofi this spring amidst an international overhaul of the company’s R&D device. Nestle, who devoted 8 years along with the pharma, jumped over to Deerfield Management, where he presently functions as a partner on the therapies staff and CEO of the agency’s therapeutic exploration and also development functions.
Quigley will definitely participate in Sanofi coming from a San Francisco-based biotech that resides in secrecy, depending on to his LinkedIn profile. He’s currently listed as the company’s co-founder, president as well as chief executive officer.Given that August 2021, Quigley has served as a venture partner at SV Health and wellness Investors, a medical care fund manager along with current assets in biotechs such as BioAge, Cerevance, Dualitas Therapies as well as Nimbus Therapies, to name a few. Quigley formerly stored the best spot at Dualitas, a biotech that continues to be in secrecy, depending on to STAT.The prospective Sanofi innovator additionally recently helmed Therini Bio, an immunotherapy biotech operating to cultivate therapies for neurodegenerative illness driven by vascular problems.Before spending the final couple of years in biotech, Quigley possesses an even longer track record in Large Pharma, very most just recently serving as Gilead’s elderly vice president of analysis biology until the summer months of 2021.
Just before that, he clocked in more than 4 years throughout various leadership roles at Bristol Myers Squibb and worked as a clinical director at Johnson & Johnson’s Janssen arm prior to that.Sanofi pointed out Quigley’s goal in his brand new job would be to “maximize our probability of effectiveness by means of optimum cooperations around our institution as well as beyond, taking best-in-class innovation and also establishing and also sourcing brand-new industry-leading talent with a dedication to diversity,” depending on to an interior memorandum acquired through STAT.